NM_000384.3:c.2068-4T>A
Variant summary
Our verdict is Benign. The variant received -9 ACMG points: 0P and 9B. BP4_StrongBP6BS2
The NM_000384.3(APOB):c.2068-4T>A variant causes a splice region, intron change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.00125 in 1,614,142 control chromosomes in the GnomAD database, including 10 homozygotes. In-silico tool predicts a benign outcome for this variant. 3/3 splice prediction tools predict no significant impact on normal splicing. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars).
Frequency
Consequence
NM_000384.3 splice_region, intron
Scores
Clinical Significance
Conservation
Publications
- hypercholesterolemia, autosomal dominant, type BInheritance: AD Classification: DEFINITIVE, STRONG Submitted by: Genomics England PanelApp, G2P, Labcorp Genetics (formerly Invitae), ClinGen, Ambry Genetics
- familial hypobetalipoproteinemia 1Inheritance: AR, AD, SD Classification: DEFINITIVE, STRONG Submitted by: PanelApp Australia, Labcorp Genetics (formerly Invitae), Genomics England PanelApp, ClinGen
- homozygous familial hypercholesterolemiaInheritance: AR Classification: SUPPORTIVE Submitted by: Orphanet
Genome browser will be placed here
ACMG classification
Our verdict: Benign. The variant received -9 ACMG points.
Transcripts
RefSeq
Ensembl
| Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | TSL | MANE | Protein | Appris | UniProt |
|---|---|---|---|---|---|---|---|---|---|---|
| APOB | ENST00000233242.5 | c.2068-4T>A | splice_region_variant, intron_variant | Intron 14 of 28 | 1 | NM_000384.3 | ENSP00000233242.1 | |||
| APOB | ENST00000399256.4 | c.2068-4T>A | splice_region_variant, intron_variant | Intron 14 of 16 | 1 | ENSP00000382200.4 | ||||
| APOB | ENST00000673739.2 | n.*1374-4T>A | splice_region_variant, intron_variant | Intron 13 of 24 | ENSP00000501110.2 | |||||
| APOB | ENST00000673882.2 | n.*1374-4T>A | splice_region_variant, intron_variant | Intron 13 of 22 | ENSP00000501253.2 |
Frequencies
GnomAD3 genomes AF: 0.00109 AC: 166AN: 152230Hom.: 0 Cov.: 32 show subpopulations
GnomAD2 exomes AF: 0.00131 AC: 328AN: 250808 AF XY: 0.00142 show subpopulations
GnomAD4 exome AF: 0.00127 AC: 1854AN: 1461794Hom.: 10 Cov.: 32 AF XY: 0.00130 AC XY: 948AN XY: 727194 show subpopulations
Age Distribution
GnomAD4 genome AF: 0.00109 AC: 166AN: 152348Hom.: 0 Cov.: 32 AF XY: 0.00103 AC XY: 77AN XY: 74494 show subpopulations
Age Distribution
ClinVar
Submissions by phenotype
not provided Benign:5
- -
APOB: BP4, BS2 -
This variant is associated with the following publications: (PMID: 18492086, 23593297, 17570373, 26332594) -
- -
- -
not specified Benign:3
Variant identified in a genome or exome case(s) and assessed due to predicted null impact of the variant or pathogenic assertions in the literature or databases. Disclaimer: This variant has not undergone full assessment. The following are preliminary notes: Not in splice consensus -
- -
BS1;BP6 -
Hypercholesterolemia, autosomal dominant, type B Uncertain:1
This variant was observed as part of a predisposition screen in an ostensibly healthy population. A literature search was performed for the gene, cDNA change, and amino acid change (where applicable). Publications were found based on this search. However, the evidence from the literature, in combination with allele frequency data from public databases where available, was not sufficient to rule this variant in or out of causing disease. Therefore, this variant is classified as a variant of unknown significance. -
APOB-related disorder Uncertain:1
The APOB c.2068-4T>A variant is predicted to interfere with splicing. The c.2068-4T>A substitution is not predicted to alter mRNA splicing (Alamut Visual plus v1.6.1). However it was reported in the compound heterozygous state in two unrelated patients with familial hypobetalipoproteinemia (FHBL) who also harbored a second protein truncating variant in the APOB gene (Tarugi et al. 2007. PubMed ID: 17570373; Di Leo et al. 2008. PubMed ID: 18492086). Di Leo et al. also showed that in vitro the c.2068-4T>A substitution did not alter normal mRNA splicing. FHBL is inherited in a co-dominant manner and is almost always associated with protein truncating variants in the APOB gene (Tarugi et al. 2007. PubMed ID: 17570373). FHBL heterozygotes may be asymptomatic or display symptoms of FHBL to varying degrees. This variant is reported in 0.19% of alleles in individuals of European (Non-Finnish) descent in gnomAD. At this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence. -
Hypercholesterolemia, autosomal dominant, type B;C4551990:Familial hypobetalipoproteinemia 1 Benign:1
- -
Hypercholesterolemia, familial, 1 Benign:1
- -
Cardiovascular phenotype Benign:1
This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. -
Familial hypercholesterolemia Benign:1
- -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at